Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M958Revenue (TTM) $M1.3Net Margin (%)-17,417.5Altman Z-Score-1.3
Enterprise Value $M850EPS (TTM) $-5.0Operating Margin %-17,400.2Piotroski F-Score1
P/E(ttm)--Beneish M-Score-1.3Pre-tax Margin (%)-17,417.5Higher ROA y-yN
Price/Book6.910-y EBITDA Growth Rate %2.4Quick Ratio2.9Cash flow > EarningsY
Price/Sales6985-y EBITDA Growth Rate %36.1Current Ratio2.9Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-95.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-133.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M45.8ROIC % (ttm)-627.5Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
$ 20.9324%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
$ 20.93-7%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
$ 20.93-34%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
$ 20.93-17%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
$ 20.93-29%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
$ 20.93-45%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
$ 20.93-27%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
$ 20.93-22%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
$ 20.93224%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
$ 20.93324%Reduce -83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
$ 20.93166%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
$ 20.93116%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BEHRENS M KATHLEENDirector 2016-03-16Buy75,000$16.2828.56view
Barry RichardDirector 2016-03-14Buy75,000$15.6633.65view
Price Ben GilDirector 2016-03-14Buy4,500$16.725.33view
Kaye Edward M. MDSVP & Chief Medical Officer 2015-02-27Buy800$11.8277.07view
Christopher Nishan GarabedianPresident and CEO 2015-02-27Buy800$11.8277.07view
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.9550.04view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.5666.64view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-43.49view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-40.15view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-35.95view

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Sarepta Shares Tumble Following FDA Committee's Decision Apr 26 2016 
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 

More From Other Websites
Is the FDA’s decision to delay Sarepta drug decision good or bad? Nobody really knows May 27 2016
Delayed FDA Decision Sends Sarepta Therapeutics Soaring May 27 2016
Sarepta: What the Bulls Say May 26 2016
Sarepta: We've Seen This Before May 26 2016
Trending Now: SRPT May 26 2016
[$$] Muscular Dystrophy Day at the FDA May 25 2016
[$$] Business Watch May 25 2016
[$$] Muscular Dystrophy Day at the FDA May 25 2016
Trade school: how to take advantage of weekly options May 25 2016
Sarepta shares soar on FDA's eteplirsen review delay May 25 2016
[$$] Sarepta Jumps on FDA Delay but Remains a Buy May 25 2016
[$$] Sarepta: FDA's Decision on Dystrophy Drug Delayed May 25 2016
Sarepta Gets Second Wind, As FDA Delays Drug Decision — Again May 25 2016
Sarepta (SRPT) Stock Spikes After FDA Delayed Approval Decision May 25 2016
[$$] How Options Investors Can Profit From Sarepta May 25 2016
Here's How to Trade 7 of the Market's Most-Active Stocks Right Now May 25 2016
Sarepta Therapeutics: Is This Why the FDA Delayed Its Decision? May 25 2016
Why is Sarepta Therapeutics (SRPT) Stock Soaring 20% Today? May 25 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)